
    
      The aim of the study in these patients with an immune mediated pharmacokinetic failure was to
      compare two strategies:

      Switch to a second anti-TNF alone or switch to a second anti-TNF with addition of
      azathioprine

      Comparing rates of clinical failure, rates of immunogenic failure and finally adverse events
      during a follow-up of 24 months
    
  